Animal Blood Plasma and Derivatives Market Trends, Demand, Growth & Future Outlook 2026–2034
Market Size
The global Animal Blood Plasma and Derivatives Market is valued at USD 1,095.00 million in 2025 and USD 1,148.56 million in 2026. The market is projected to reach USD 1,655.52 million by 2034, registering a CAGR of 4.70% during the forecast period from 2026 to 2034.
The market covers the collection, separation, purification, and commercialization of blood-derived materials obtained from livestock and other animals. Key products include immunoglobulin, fibrinogen, serum albumin, fetal bovine serum, thrombin, and other specialized biological fractions. These materials serve customers across animal nutrition, pet food, food processing, pharmaceuticals, diagnostics, biotechnology, and research.
Animal blood is also an important animal-by-product stream within the circular bioeconomy. Appropriate processing enables the recovery of nutritional and energetic value while supporting applications across feed, food, pharmaceutical, research, and other industries.
Key Takeaways
The global market was valued at USD 1,148.56 million in 2026 and is projected to reach USD 1,655.52 million by 2034.
The market is expected to register a 4.70% CAGR during 2026–2034.
Immunoglobulin accounted for 33% of the 2026 market, equivalent to USD 379.02 million.
Animal Feed represented the largest application with 35% share in 2026, equivalent to USD 402.00 million.
North America accounted for 32% of the 2026 market, making it the largest regional market.
APAC represented 28% of the market in 2026 and is projected to grow at the highest regional CAGR of 5.27%.
APAC is projected to increase its market share to 31% by 2034.
The market is supported by functional plasma proteins, slaughter by-product valorization, pet-food applications, and life-science and biomanufacturing demand.
Request Sample
Market Drivers
Functional Plasma Proteins Are Gaining Importance in Animal Nutrition
Spray-dried plasma is increasingly used as a functional animal-nutrition ingredient rather than simply as a conventional protein source. Plasma applications span swine, poultry, ruminants, aquaculture, and companion animals.
Young-animal diets represent an important opportunity because feed intake, gut integrity, and immune status can influence subsequent growth performance. Research on plasma supplementation in nursery-pig diets has also supported broader evaluation of plasma products across the nursery feeding cycle.
This gives plasma a differentiated commercial position because feed manufacturers can use the ingredient for nutritional and functional purposes simultaneously. Demand therefore extends beyond protein replacement toward feed performance, digestibility, and animal resilience.
Pet-Food Manufacturers Are Expanding the Use of Functional Animal Proteins
The pet-food industry increasingly uses animal-origin ingredients for protein quality, palatability, texture, moisture management, and functional nutrition. Plasma-derived ingredients can serve broader formulation objectives involving water retention, emulsification, palatability, and nutritional performance.
The growth of premium pet food also creates opportunities for differentiated animal-origin ingredients with documented composition, traceability, and application performance. This favors producers that can supply standardized plasma products rather than commodity blood meal alone.
Slaughter By-Product Valorization Is Strengthening the Economics of Blood Processing
Animal blood is generated during slaughter and can be recovered into plasma, hemoglobin, red-cell products, and other fractions instead of being treated primarily as a disposal stream.
This creates an economic incentive for vertically integrated processors. A single raw-material stream can supply several differentiated products serving feed, pet food, food, pharmaceutical, and technical applications. The value of blood therefore increases when processors can separate fractions and match outputs with higher-value end markets.
Market Restraints
Biosafety and Animal-By-Product Regulation Increase Processing Complexity
Blood-derived ingredients require stringent controls because untreated animal material can carry pathogens. Regulations governing blood products intended for animal feed require specified processing and microbiological requirements.
These controls increase costs through validated processing, microbiological testing, traceability, approved facilities, storage requirements, and certification. International suppliers must also manage different import and animal-health requirements across destination markets.
Raw-Material Quality and Supply Are Closely Tied to Livestock and Slaughter Activity
The supply of animal blood depends on livestock populations, slaughter volumes, processing locations, and animal-health conditions. Regional disruptions in livestock production or restrictions on animal movement can influence raw-material availability and quality.
For high-purity serum products, quality requirements are particularly demanding. FBS specifications can include defined country of origin, sterile filtration, virus and mycoplasma testing, endotoxin limits, and additional irradiation or processing requirements.
Market Opportunities
Higher-Value Plasma Fractions and Application-Specific Ingredients
The market is moving toward greater specialization in plasma-derived products. Different plasma formats and blood-derived proteins can serve applications across swine, poultry, aquaculture, and companion animals.
Manufacturers can increase value by tailoring products around species, animal age, feed format, processing requirements, or targeted functional properties. Granulated and specialized plasma products can also improve handling, blending, and dosing compared with conventional powders.
Life-Science and Biomanufacturing Applications
Animal serum and purified plasma proteins continue to serve cell culture, research, and biotechnology applications. Fetal bovine serum products are differentiated by origin, filtration, irradiation, and testing specifications.
Products with controlled origin, high purity, validated filtration, irradiation, and detailed documentation can address higher-value pharmaceutical and bioprocessing requirements. Customers in these environments place greater emphasis on lot consistency and traceability.
Challenges in Animal Blood Plasma and Derivatives Market
Maintaining Biosafety, Quality, and Supply Consistency
Manufacturers must maintain consistent quality while processing biological raw materials from different livestock and geographic sources. Regulatory requirements, pathogen controls, traceability, processing validation, and specialized testing add complexity to production.
High-purity products intended for diagnostics, biotechnology, pharmaceutical, and research applications require additional qualification and documentation. At the same time, feed and pet-food applications require reliable large-scale supply and competitive pricing.
Derivative Type Segment Analysis
Immunoglobulin
The Immunoglobulin segment accounts for 33% of the 2026 market, equivalent to USD 379.02 million, and is projected to reach 34% by 2034, equivalent to USD 531.76 million. The segment is projected to register a 4.32% CAGR.
Immunoglobulins are important components of plasma because of their biological and functional properties. In animal nutrition, plasma-derived immunoglobulins contribute to the functional value of spray-dried plasma, while research and biological applications use them as components of specialized plasma and serum products.
Fibrinogen
The Fibrinogen segment represents 15% of the 2026 market, equivalent to USD 172.28 million, and is projected to reach 17% by 2034, equivalent to USD 265.88 million. The segment is projected to grow at a 5.57% CAGR.
Fibrinogen is a plasma protein associated with coagulation and fibrin formation and is used in specialized biological, diagnostic, and research applications. Its commercial value is influenced by purity, consistency, and processing quality.
Serum Albumin
The Serum Albumin segment accounts for 25% of the 2026 market, representing USD 287.14 million, and reaches 25% by 2034, representing USD 391.00 million. The segment is projected to grow at a 3.93% CAGR.
Serum albumin is used across life-science applications as a protein component and stabilizing material. Bovine-derived albumin and serum products across major life-science portfolios support continued demand for purified animal proteins.
Application Analysis
Animal Feed
The Animal Feed segment accounts for 35% of the 2026 market, equivalent to USD 402.00 million, and reaches 34% by 2034, equivalent to USD 531.76 million. The segment is projected to grow at a 3.56% CAGR.
Animal feed is the largest application because spray-dried plasma is used as both a protein ingredient and a functional component in livestock, poultry, and aquaculture diets. Plasma applications span multiple animal species, while research continues to evaluate plasma's effects on performance, digestibility, and health.
Pharmaceuticals
The Pharmaceuticals segment represents 25% of the 2026 market, equivalent to USD 287.14 million, and reaches 27% by 2034, equivalent to USD 422.28 million. The segment is projected to grow at a 4.94% CAGR.
Pharmaceutical and biotechnology customers require animal-derived proteins and serum products with consistent specifications, traceability, and controlled processing. FBS products demonstrate how animal-derived materials can be differentiated through origin, filtration, irradiation, and testing.
Food & Beverages
The Food & Beverages segment accounts for 15% of the 2026 market, equivalent to USD 172.28 million, and remains at 15% in 2034, equivalent to USD 234.60 million. The segment is projected to grow at a 3.93% CAGR.
Animal plasma proteins can provide functional characteristics such as emulsification, water retention, binding, and texture modification in food formulations. These applications require controlled processing and consistent quality, creating demand for specialized blood-derived ingredients.
Regional Analysis
North America
The North America market represents 32% of the 2026 global market, equivalent to USD 367.54 million, and reaches 30% by 2034, equivalent to USD 469.20 million. The regional market is projected to grow at a 3.10% CAGR.
North America represents the largest regional market due to its livestock-processing base, established animal-feed industry, developed rendering infrastructure, and substantial biotechnology and life-science ecosystem.
Europe
The Europe market accounts for 24% of the 2026 market, equivalent to USD 275.65 million, and reaches 23% by 2034, equivalent to USD 359.72 million. The market is projected to grow at a 3.38% CAGR.
Europe has a mature animal-by-product processing industry and a comprehensive regulatory framework governing blood and other animal-derived materials. Regulatory requirements covering approved establishments, processing, and end uses support structured market development.
APAC
The APAC market represents 28% of the 2026 market, equivalent to USD 321.60 million, and increases to 31% by 2034, equivalent to USD 484.84 million. The region is projected to grow at a 5.27% CAGR.
APAC is the fastest-growing regional market as livestock production, poultry, aquaculture, pet food, and biotechnology activity expand across the region. The growing commercialization of animal-derived proteins and increasing interest in functional feed ingredients support regional demand.
Middle East and Africa
The Middle East and Africa market represents 8% of the 2026 market, equivalent to USD 91.88 million, and reaches 8% in 2034, equivalent to USD 125.12 million. The regional market is projected to grow at a 3.93% CAGR.
The market is supported by livestock and poultry production, feed-industry modernization, and rising demand for standardized functional animal ingredients. Suppliers with reliable logistics and validated processing systems can serve markets where local blood-fractionation infrastructure is less developed.
LATAM
The LATAM market represents 8% of the 2026 market, equivalent to USD 91.88 million, and reaches 8% in 2034, equivalent to USD 125.12 million. The region is projected to grow at a 3.93% CAGR.
Latin America has significant livestock, poultry, pork, and aquaculture production, providing raw-material availability for animal-protein processing. Regional processors can convert slaughter by-products into feed, pet-food, and specialty protein ingredients.
Top Players
Darling Ingredients / Sonac
APC
SARIA Group
VEOS Group
Lican Food
Bovogen Biologicals
Merck KGaA / Sigma-Aldrich
Thermo Fisher Scientific
Proliant
Kraeber & Co.
Rocky Mountain Biologicals
Lake Immunogenics
LAMPIRE Biological Laboratories
ANZCO Foods Healthcare
Essentia Protein Solutions
Recent Developments
September 2026: SARIA agreed to acquire a 36.45% stake in Chilean fish by-product processor Fiordo Austral. The transaction expands SARIA's presence in Latin America and the marine-ingredients sector.
June 2026: APC released research on extending plasma supplementation in nursery pig diets. The company reported improved nursery-pig growth outcomes when plasma supplementation continued beyond the first two weeks following weaning.
The supplied source also highlights continued development of plasma applications across livestock, poultry, aquaculture, companion animals, biotechnology, and life-science markets.
Market Segments
By Derivative Type
Immunoglobulin
Fibrinogen
Serum Albumin
Fetal Bovine Serum
Thrombin
Others
By Animal Type
Bovine
Porcine
Ovine
Poultry
Others
By Application
Animal Feed
Pharmaceuticals
Food & Beverages
Pet Food
Diagnostics & Research
Others
By Region
North America
Europe
APAC
Middle East and Africa
LATAM
Frequently Asked Questions
What is the size of the Animal Blood Plasma and Derivatives Market?
The global Animal Blood Plasma and Derivatives Market is valued at USD 1,095.00 million in 2025 and USD 1,148.56 million in 2026. It is projected to reach USD 1,655.52 million by 2034, registering a CAGR of 4.70% during the forecast period.
What is driving the Animal Blood Plasma and Derivatives Market?
The market is supported by the growing use of functional plasma proteins in animal nutrition, increasing applications in pet food, slaughter by-product valorization, and demand for animal serum and purified plasma proteins in pharmaceutical, biotechnology, diagnostics, and research applications.
Which derivative type holds the largest share?
Immunoglobulin is the largest specified derivative segment, accounting for 33% of the 2026 market, equivalent to USD 379.02 million.
Which application represents the largest share?
Animal Feed is the largest application segment, accounting for 35% of the 2026 market, equivalent to USD 402.00 million.
Which region is projected to grow at the highest CAGR?
APAC is projected to grow at the highest regional CAGR of 5.27% during the forecast period, increasing its market share from 28% in 2026 to 31% by 2034.
Conclusion
The global Animal Blood Plasma and Derivatives Market is projected to grow from USD 1,148.56 million in 2026 to USD 1,655.52 million by 2034, registering a CAGR of 4.70%. Market development is supported by the increasing use of functional plasma proteins in animal nutrition, expansion of pet-food applications, slaughter by-product valorization, and demand for purified animal-derived materials in pharmaceutical and life-science applications.
Immunoglobulin remains the largest specified derivative segment, while Animal Feed represents the largest application. North America currently accounts for the largest regional share, while APAC is projected to record the highest regional CAGR and increase its share through 2034.
Report URL
https://reedintelligence.com/market-analysis/animal-blood-plasma-and-derivatives-market
